RNA-guided transcriptional silencing in vivo with S. aureus CRISPR-Cas9 repressors

被引:120
作者
Thakore, Pratiksha I. [1 ,2 ]
Kwon, Jennifer B. [2 ,3 ]
Nelson, Christopher E. [1 ,2 ]
Rouse, Douglas C. [4 ]
Gemberling, Matthew P. [1 ,2 ]
Oliver, Matthew L. [1 ]
Gersbach, Charles A. [1 ,2 ,5 ]
机构
[1] Duke Univ, Dept Biomed Engn, Durham, NC 27708 USA
[2] Duke Univ, Ctr Genom & Computat Biol, Durham, NC 27708 USA
[3] Duke Univ, Univ Program Genet & Genom, Med Ctr, Durham, NC 27710 USA
[4] Duke Univ, Sch Med, Div Lab Anim Resources, Durham, NC 27710 USA
[5] Duke Univ, Med Ctr, Dept Orthopaed Surg, Durham, NC 27710 USA
来源
NATURE COMMUNICATIONS | 2018年 / 9卷
基金
美国国家卫生研究院; 美国国家科学基金会;
关键词
GENE ACTIVATION; MOUSE MODEL; FACTOR-IX; GENOME; PCSK9; EXPRESSION; TECHNOLOGIES; HEMOPHILIA; MUSCLE;
D O I
10.1038/s41467-018-04048-4
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
CRISPR-Cas9 transcriptional repressors have emerged as robust tools for disrupting gene regulation in vitro but have not yet been adapted for systemic delivery in adult animal models. Here we describe a Staphylococcus aureus Cas9-based repressor (dSaCas9(KRAB)) compatible with adeno-associated viral (AAV) delivery. To evaluate dSaCas9(KRAB) efficacy for gene silencing in vivo, we silenced transcription of Pcsk9, a regulator of cholesterol levels, in the liver of adult mice. Systemic administration of a dual-vector AAV8 system expressing dSaCas9(KRAB) and a Pcsk9-targeting guide RNA (gRNA) results in significant reductions of serum Pcsk9 and cholesterol levels. Despite a moderate host response to dSaCas9(KRAB) expression, Pcsk9 repression is maintained for 24 weeks after a single treatment, demonstrating the potential for long-term gene silencing in post-mitotic tissues with dSaCas9(KRAB). In vivo programmable gene silencing enables studies that link gene regulation to complex phenotypes and expands the CRISPR-Cas9 perturbation toolbox for basic research and gene therapy applications.
引用
收藏
页数:9
相关论文
共 51 条
  • [1] Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
    Abifadel, M
    Varret, M
    Rabès, JP
    Allard, D
    Ouguerram, K
    Devillers, M
    Cruaud, C
    Benjannet, S
    Wickham, L
    Erlich, D
    Derré, A
    Villéger, L
    Farnier, M
    Beucler, I
    Bruckert, E
    Chambaz, J
    Chanu, B
    Lecerf, JM
    Luc, G
    Moulin, P
    Weissenbach, J
    Prat, A
    Krempf, M
    Junien, C
    Seidah, NG
    Boileau, C
    [J]. NATURE GENETICS, 2003, 34 (02) : 154 - 156
  • [2] Inheritable Silencing of Endogenous Genes by Hit-and-Run Targeted Epigenetic Editing
    Amabile, Angelo
    Migliara, Alessandro
    Capasso, Paola
    Biffi, Mauro
    Cittaro, Davide
    Naldini, Luigi
    Lombardo, Angelo
    [J]. CELL, 2016, 167 (01) : 219 - +
  • [3] Differential expression analysis for sequence count data
    Anders, Simon
    Huber, Wolfgang
    [J]. GENOME BIOLOGY, 2010, 11 (10):
  • [4] The AAV Vector Toolkit: Poised at the Clinical Crossroads
    Asokan, Aravind
    Schaffer, David V.
    Samulski, R. Jude
    [J]. MOLECULAR THERAPY, 2012, 20 (04) : 699 - 708
  • [5] Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases
    Bae, Sangsu
    Park, Jeongbin
    Kim, Jin-Soo
    [J]. BIOINFORMATICS, 2014, 30 (10) : 1473 - 1475
  • [6] Versatile in vivo regulation of tumor phenotypes by dCas9-mediated transcriptional perturbation
    Braun, Christian J.
    Bruno, Peter M.
    Horlbeck, Max A.
    Gilbert, Luke A.
    Weissman, Jonathan S.
    Hemann, Michael T.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2016, 113 (27) : E3892 - E3900
  • [7] Chavez A, 2015, NAT METHODS, V12, P326, DOI [10.1038/NMETH.3312, 10.1038/nmeth.3312]
  • [8] A multifunctional AAV-CRISPR-Cas9 and its host response
    Chew, Wei Leong
    Tabebordbar, Mohammadsharif
    Cheng, Jason K. W.
    Mali, Prashant
    Wu, Elizabeth Y.
    Ng, Alex H. M.
    Zhu, Kexian
    Wagers, Amy J.
    Church, George M.
    [J]. NATURE METHODS, 2016, 13 (10) : 868 - +
  • [9] Sequence variations in PCSK9, low LDL, and protection against coronary heart disease
    Cohen, JC
    Boerwinkle, E
    Mosley, TH
    Hobbs, HH
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (12) : 1264 - 1272
  • [10] Multiplex Genome Engineering Using CRISPR/Cas Systems
    Cong, Le
    Ran, F. Ann
    Cox, David
    Lin, Shuailiang
    Barretto, Robert
    Habib, Naomi
    Hsu, Patrick D.
    Wu, Xuebing
    Jiang, Wenyan
    Marraffini, Luciano A.
    Zhang, Feng
    [J]. SCIENCE, 2013, 339 (6121) : 819 - 823